地西他滨联合CHG方案治疗中高危老年急性髓系白血病的临床效果

Abstract
Figure/Table
References (17)
Related Citation (15)

Download: PDF (0 KB) HTML (37 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Decitabine combined with CHG regimen in the treatment of medium or high risk elderly acute myeloid leukemia (AML).Methods From June 2016 to June 2019, 60 elderly patients with acute moderate to high risk AML admitted to Central Hospital of Anshan city were included as the research objects, and divided into Decitabine combined CHG regimen treatment group (32 cases) and monotherapy group (28 cases) according to the random number table method.The Decitabine combined with CHG regimen treatment group was treated with Decitabine 20 mg/(m2·d) combined with CHG regimen chemotherapy, while the monotherapy group was only treated with Decitabine single drug, and the dosage was the same as that of the Decitabine combined with CHG regimen treatment group.The clinical effects, blood picture recovery time and adverse reactions of the two groups after one course of treatment were compared.Results There was no significant difference in the total effective rate between the two groups(P＞0.05).There were no significant difference in recovery time of platelets and leukocytes between the two groups(P＞0.05).The incidence of infection in patients of the Decitabine combined with CHG regimen treatment group was higher than that in patients of the monotherapy group,the difference was statistically significant(P＜0.05),while there were no statistically significant difference in liver function damage, nausea, vomiting, constipation, fatigue incidence and mortality between the two groups (P＞0.05).Conclusion After completing one course of treatment, the total effective rate of Decitabine combined with CHG regimen treatment group did not improve, but the incidence of infection may be greater.

Key words： Decitabine Acute myeloid leukemia Hypomethylation Elderly patients

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YAN Chao-qi
	LENG Qing
	JI Zheng
	WU Yin
	ZHANG Li-jun

Cite this article:

YAN Chao-qi,LENG Qing,JI Zheng, et al. Clinical effect of Decitabine combined with CHG regimen in the treatment of medium or high risk elderly acute myeloid leukemia[J]. 中国当代医药, 2020, 27(3): 125-128.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I3/125

[1]	Dohner H，Estey E，Grimwade D，et al.Diagnosis and management of AML in adults：2017 ELN recommendations from an international expert panel[J].Blood，2017，129（4）：424-447.
[2]	Hollenbach PW，Nguyen AN，Brady H，et al.A comparison of azacitidine and Decitabine activities in acute myeloid leukemia cell lines[J].PLoS One，2010，5（2）：e9001.
[3]	Kim TK，Gore SD，Zeidan AM.Epigenetic therapy in acute myeloid leukemia： current and future directions[J].Semin Hematol，2015，52（3）：172-183.
[4]	Ferrara F，Barosi G，Venditti A，et al.Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia：a project of SIE，SIES and GITMO group on a new tool for therapy decision making[J].Leukemia，2013，27（5）：997-999.
[5]	张之南，沈悌.血液病诊断及疗效标准[M].3 版，北京：科学出版社，2007：131-134.
[6]	National Cancer Institute.Cancer stat facts.https：//seer.cancer.gov/statfacts/html/amyl.html.Updated 2018.Accessed2/8，2019.
[7]	Miyamoto T，Kikushige Y，Yoshimoto AG.Frontline treatment of AML in adults[J].Rinsho Ketsueki，2017，58（10）：1884-1894.
[8]	Short NJ，Kantarjian HM，Loghavi S，et al.Treatment with a 5-day versus a 10-day schedule of Decitabine in older patients with newly diagnosed acute myeloid leukaemia：a randomised phase 2 trial[J].Lancet Haematol，2019，6（1）：e29-e37.
[9]	李学琴，黄鑫.小剂量HAG 方案联合地西他滨治疗15 例老年AML 的疗效及安全性分析[J].解放军预防医学杂志，2019，37（7）：18-19.
[10]	崔巍，金正明，曹晶，等.地西他滨联合HAAG 方案治疗进展期AML 疗效分析[J].第三军医大学学报，2016，38（12）：1379-1384.
[11]	孙妍珺，徐杨，吴德沛，等.地西他滨联合预激方案治疗53 例复发难治正常核型AML 的疗效分析[J].中华血液学杂志，2015，36（12）：1025-1030.
[12]	Dombret H，Seymour JF，Butrym A，et al.International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with>30%blasts[J].Blood，2015，126（3）：291-299.
[13]	Kantarjian HM，Thomas XG，Dmoszynska A，et al.Multicenter，randomized，open-label，phase Ⅲtrial of Decitabine versus patient choice，with physician advice，of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia[J].J Clin Oncol，2012，30（21）：2670-2677.
[14]	Santini V，Ossenkoppele GJ.Hypomethylating agents in the treatment of acute myeloid leukemia：A guide to optimal use.Critical Reviews in Oncology/Hematolog[J].Crit Rev Oncol Hematol，2019，140：1-7.
[15]	Nieto M，Demolis P，Behanzin E，et al.The European Medicines Agency Review of Decitabine（Dacogen）for the Treatment of Adult Patients With Acute Myeloid Leukemia：Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use[J].Oncologist，2016，21（6）：692-700.
[16]	He J，Xiu L，Porre PD，et al.Decitabine reduces transfusion dependence in older patients with acute myeloid leukemia：results from a post hocanalysis of a randomized phaseⅢstudy[J].Leuk Lymphoma，2015，56（4）：1033-1042.
[17]	Jabbour E，Ghanem H，Huang X，et al.Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents：an emerging entity with a poor prognosis[J].Clin Lymphoma Myeloma Leuk，2014，14（2）：93-97.